Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Depreciation and Depletion (2022 - 2024)

Centessa Pharmaceuticals (CNTA) has disclosed Depreciation and Depletion for 3 consecutive years, with $48000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Depreciation and Depletion fell 47.83% to $48000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $300000.0, a 0.0% change, with the full-year FY2024 number at $300000.0, changed 0.0% from a year prior.
  • Depreciation and Depletion was $48000.0 for Q4 2024 at Centessa Pharmaceuticals, down from $82000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $92000.0 in Q4 2023 to a low of $28000.0 in Q1 2022.
  • A 3-year average of $60916.7 and a median of $65000.0 in 2024 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: soared 162.5% in 2023, then tumbled 47.83% in 2024.
  • Centessa Pharmaceuticals' Depreciation and Depletion stood at $36000.0 in 2022, then skyrocketed by 155.56% to $92000.0 in 2023, then crashed by 47.83% to $48000.0 in 2024.
  • Per Business Quant, the three most recent readings for CNTA's Depreciation and Depletion are $48000.0 (Q4 2024), $82000.0 (Q3 2024), and $84000.0 (Q2 2024).